CompletedEarly (CIS/RIS)NCT01414816

What it found

No result found

We found no results in the registry or in papers.

This trial finished 14 years ago. We found no results in the registry or in any paper that cites it.

What was tested

Treatment tested

What it measured

Main measures

  • Safety variables will be summarized using descriptive statistics based on adverse events.

    Up to 6 months

    Safety

Other measures (2)

  • The efficacy data regarding prevention of relapse due to MS will be estimated based on the number of relapse.

    During 6 month

    Relapses
  • Progression or aggravation to Multiple sclerosis (MS) will be identified based on the change of Expanded Disability Status Scale (EDSS) and the Magnetic Resonance Imaging (MRI) outcome.

    0, 6 month

    Disability progressionMRI lesions

Who could take part

Early (CIS/RIS) · 12 and over

Inclusion Criteria: * Patients with diagnosis of MS or CIS and decision taken by the physician to prescribe Betaferon * Patients who have not participated in Betaferon regulatory Post Marketing Surveillance before. Exclusion Criteria: * Exclusion criteria must be read in conjunction with local product information

As registered. Criteria can change, so ask the trial team or your neurologist.

About this trial

In the sponsor's words

To identify problems/questions about following items in the clinical practice using Betaferon 1. Unknown adverse event (especially serious adverse event) 2. Identification of adverse event occurred in the real practice 3. Factors that may affect the safety of drug 4. Factors that may affect the effectiveness of the drug

Loading reviews and guidelines…

Related trials

History

    1. Started

      Apr 2008

    2. Main results due

      Jul 2012

    3. Finished

      Jul 2012

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error